Jefferies Group Reiterates Hold Rating for Enzymotec Ltd. (ENZY)
Enzymotec Ltd. (NASDAQ:ENZY)‘s stock had its “hold” rating reissued by Jefferies Group in a report issued on Monday. They presently have a $7.00 target price on the stock, down from their prior target price of $8.00. Jefferies Group’s price target indicates a potential upside of 11.11% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Enzymotec from a “hold” rating to a “sell” rating in a report on Monday, November 21st. Wells Fargo & Co. downgraded Enzymotec from an “outperform” rating to a “market perform” rating in a report on Thursday, November 17th.
Shares of Enzymotec (NASDAQ:ENZY) opened at 6.30 on Monday. The company has a 50 day moving average of $6.65 and a 200-day moving average of $7.66. The stock has a market cap of $143.38 million, a price-to-earnings ratio of 58.88 and a beta of 1.26. Enzymotec has a one year low of $5.20 and a one year high of $10.32.
Enzymotec (NASDAQ:ENZY) last released its earnings results on Wednesday, November 16th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by $0.04. Enzymotec had a net margin of 4.82% and a return on equity of 1.95%. The business earned $11.40 million during the quarter, compared to analyst estimates of $13.29 million. During the same period last year, the business posted $0.08 EPS. Enzymotec’s revenue was down 8.1% compared to the same quarter last year. On average, analysts anticipate that Enzymotec will post $0.18 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/30/jefferies-group-reiterates-hold-rating-for-enzymotec-ltd-enzy.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENZY. Tiger Management L.L.C. increased its position in Enzymotec by 17.3% in the third quarter. Tiger Management L.L.C. now owns 677,548 shares of the company’s stock valued at $4,743,000 after buying an additional 100,141 shares during the period. Janus Capital Management LLC increased its position in Enzymotec by 79.3% in the second quarter. Janus Capital Management LLC now owns 248,485 shares of the company’s stock valued at $2,077,000 after buying an additional 109,933 shares during the period. Acadian Asset Management LLC increased its position in Enzymotec by 47.2% in the second quarter. Acadian Asset Management LLC now owns 248,317 shares of the company’s stock valued at $2,076,000 after buying an additional 79,579 shares during the period. Gagnon Securities LLC purchased a new position in Enzymotec during the second quarter valued at about $2,022,000. Finally, Gagnon Advisors LLC purchased a new position in Enzymotec during the second quarter valued at about $1,590,000. 35.93% of the stock is owned by institutional investors and hedge funds.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.